BGIN vs IBEX

The company exhibits weak financial health with a Piotroski F-Score of 4/9, indicating marginal stability at best, while the absence of an Altman Z-Score prevents a full distress risk assessment. BGIN is unprofitable, with a negative profit margin of -28.17% and an operating margin of -88.65%, alongside a sharp year-over-year revenue decline of 67%. Despite a strong current ratio of 3.06, liquidity is questionable due to a low quick ratio of 0.62 and missing cash flow data. Valuation metrics are elevated relative to peers, with no earnings to support P/E or PEG analysis, and the stock has underperformed significantly over the past year despite a recent one-month rebound.

IBEX exhibits exceptional fundamental health with a Piotroski F-Score of 8/9, indicating strong financial stability and operational efficiency. The stock is currently trading at $27.49, which is essentially at its Graham Number ($27.9) and significantly below its growth-based intrinsic value of $88.79. Despite a bearish technical trend and recent insider selling by the CEO, the combination of a low P/E (9.13), high ROE (33.65%), and robust earnings growth (45.6% YoY) presents a compelling value opportunity.